Send us an enquiry

Use the form below . Every submission is personally reviewed and routed to the right team member.

I represent…

Context
✓ Email verified

Enter the 6-digit code we sent to .

Response within 2 business days.
All submissions are personally reviewed.
✓

Enquiry Received

Thank you. Your enquiry has been received and routed to the right team member. We will respond within two business days. If your matter is time-sensitive, email us directly at corporate@zoyel.one.

Who We Work With

Every enquiry type has a dedicated path.

ZoyeMed 3.0 is an institutional product. We work with a defined set of partner types - each with different timelines, requirements, and disclosure needs.

Government
Ministry of Health & Public Sector
National healthcare infrastructure programmes, underserved geography deployments, and population-level epidemiological intelligence layers.
  • National deployment programmes
  • Real-time health intelligence
  • Data sovereignty architecture
  • Pilot-to-programme scale-up
Start Discussion →
Health Systems
Hospital Health Systems & Doctors
Fleet deployment across multi-site hospital networks. ZoyeMed integrates with existing HIS/EMR via FHIR R4. Programmes start at 25 units; typical fleets run 100+ units.
  • Fleet programmes from 25 units
  • FHIR R4 EMR integration
  • Operator training programme
  • Ongoing PMCF data support
Start Discussion →
Investors
Investors & Growth Capital
Financial model, deployment pipeline, revenue structure, and commercial agreements. Routed directly to CEO and CFO. NDA required for financial disclosure.
  • Financial model (NDA required)
  • Deployment pipeline & backlog
  • Commercial contract structure
  • IP & regulatory asset review
Start Discussion →
Press
Press, Media & Analysts
Media briefings, press kit access, executive interview requests, and PMCF clinical summary for verified publications. Mark email subject: PRESS for priority routing.
  • Press kit & assets
  • PMCF public summary
  • Executive interview requests
  • Technical background briefings
Request Access →
Technical
Technical & Regulatory Reviewers
Architecture documentation, FHIR interoperability specs, safety gate design, PHI handling protocol, and regulatory dossier access. Routed to CTO and Head of Regulatory.
  • Technical White Paper (verified email)
  • Architecture documentation (NDA)
  • Regulatory submission support
  • FHIR R4 integration specs
Request Access →
Distribution
Distributors & Channel Partners
In-country distribution, localisation, regulatory navigation, and commercial channel partnerships. ZoyeMed is currently expanding institutional channel coverage across MENA, Southeast Asia, and Latin America.
  • In-country distribution rights
  • Regulatory localisation support
  • Commercial channel terms
  • MENA · SEA · LATAM focus
Start Discussion →

Document Access

Evidence for serious reviewers.

Clinical documents are tiered by sensitivity. Public materials are freely accessible. Technical materials require verified institutional access. Commercially sensitive materials require NDA and a discovery call.

Tier 1 · Public
Clinical White Paper - February 2026
Overview of ZoyeMed 3.0 clinical architecture, PMCF summary, and institutional deployment evidence. Freely accessible. No form required.
Download PDF →
Tier 1 · Public
SSRN Preprint
Peer-reviewed academic preprint on the ZoyeMed clinical AI architecture. Available on SSRN. Link delivered via email - provide any email address to receive it.
Tier 2 · Verified Email
Technical White Paper
"The Category Nobody Else Is Building" - 13-platform competitive analysis with full PMCF data. Delivered to verified corporate email via OTP.
Tier 2 · Verified Email
Interactive 3D Terminal Model
Interactive 3D model of the ZoyeMed 3.0 terminal - sensor positioning, operator workflow, and physical footprint. Access granted on verified corporate email.
Tier 3 · NDA + Call
Full PMCF Report
Complete Post-Market Clinical Follow-up report - 18,224 consultations in the Mexico institutional programme (Mar 2025 – Feb 2026). Patient-level data requires NDA and discovery call.
Tier 3 · NDA + Call
Financial Model & IP Disclosure
Commercial financial projections and IP technical disclosure. Commercially sensitive. Requires executed NDA and scheduled discovery call with the CEO/CFO team.

Common Questions

Before you reach out.

What is the minimum deployment size?
Programmes start at 25 units, with three demonstration sets available for evaluation; the deployments we serve best run 100+ units. Smaller pilot programmes are considered on a case-by-case basis for qualified institutional partners with a clear path to fleet scale-up. Contact us to discuss your specific programme.
Why do you require a corporate email?
ZoyeMed is an institutional product. Document access and briefing requests are gated to verified institutional email addresses to ensure materials reach qualified reviewers. If you have a legitimate need but no corporate email, contact corporate@zoyel.one directly.
How long does a deployment take to stand up?
From signed agreement to first clinical encounters is typically 90-120 days for a fleet deployment, covering logistics, regulatory clearance, operator training, and HIS integration. The full timeline is discussed during the discovery call.
What regulatory certifications does ZoyeMed hold?
ZoyeMed 3.0 currently holds CE Electrical and NYCE Mexico certifications. Zoyel.Health is licensed as Class B SaMD under India's CDSCO framework; CE Medical Device (MDR) for the integrated configuration, COFEPRIS Mexico and INVIMA Colombia are in process. See the About page for full status.
Does ZoyeMed require cloud connectivity?
No. Primary clinical AI inference runs entirely on-device - no cloud dependency for the consultation itself. Aggregate anonymised data can optionally be transmitted to an institutional or national health intelligence platform, subject to data residency configuration.
Is the PMCF report publicly available?
A public summary is available in the Clinical White Paper (Tier 1 - free download). The full PMCF report with patient-level aggregate data is available to qualified institutional reviewers under NDA following a discovery call.
We're a small clinic / NGO with no corporate email - can we still reach you?
Yes. Email corporate@zoyel.one directly. Our team will assess the enquiry and issue document access manually for legitimate small-organisation cases. We do not build automatic bypasses, but we do make case-by-case judgements.
Where is Zoya Technologies headquartered?
Zoya Technologies LLC is headquartered in Dubai, United Arab Emirates. The company was founded in 2022, building on the clinical lineage of Glocal Healthcare Systems (India, 2010). Active deployments are in Mexico and Colombia; Zoya Technologies Malaysia Sdn Bhd operates from Kuala Lumpur.
Zoyel® and ZoyeMed® are registered trademarks of Zoya Technologies LLC (India, China, UAE). The ZoyeMed terminal is general-purpose clinical IT infrastructure, device-agnostic by design, deployed with separately certified medical device and IVD modules supplied under each manufacturer's own conformity marking. Terminal hardware: CE Electrical and NYCE Mexico certified; integrated-configuration CE-MDR assessment, COFEPRIS (Mexico) and INVIMA (Colombia) in process. Zoyel.Health is licensed as Class B Software as a Medical Device under India's CDSCO framework. Zoyel.Health provides clinical decision support; final diagnostic and prescribing decisions remain with a licensed clinician. Regulatory status varies by jurisdiction. Zoyel SSM is delivered jointly by Zoya Technologies LLC and Zoya Technologies Malaysia Sdn Bhd. Longitudinal multimodal model architecture: PCT application filed Q1 2026. Nothing on this site is an offer; commercial terms are set only in a signed agreement.
✓
Enquiry Submitted
We'll respond within two business days.